[1] Dyck CH van, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine, 2023; 388, 9−21.
[2] Adepoju V, Okechukwu IO, Jamil S, et al. Lecanemab Unveiled: Exploring Alzheimer’s Treatment Advancements, Assessing Strengths, Limitations, and Its Therapeutic Landscape Position. Biomed Environ Sci, 2024; 37, 428−31.
[3] Heneka MT, van der Flier WM, Jessen F, et al. Neuroinflammation in Alzheimer disease. Nat Rev Immunol, 2025; 25, 321−52.
[4] Smith EE, Biessels GJ, Gao V, et al. Systemic determinants of brain health in ageing. Nat Rev Neurol, 2024; 20, 647−59. doi:  10.1038/s41582-024-01016-z
[5] Zu J, Li C, Cui MC, et al. Pioglitazone attenuates complement-mediated microglial synaptic engulfment in an Alzheimer’s disease model. Brain, 2026; 149, 668−79.
[6] Jorfi M, Park J, Hall CK, et al. Infiltrating CD8+ T cells exacerbate Alzheimer’s disease pathology in a 3D human neuroimmune axis model. Nat Neurosci. 2023; 26, 1489-504.
[7] Zhang XM, Liu J, Cao M, et al. TREM2: a novel potential biomarker of Alzheimer’s disease. Biomed Environ Sci, 2021; 34, 719−24.
[8] Liu C, Wang P, Ma H. Monocyte-to-albumin ratio Is associated with cognitive function in adults aged over 60. Biomed Environ Sci, 2026; 39, 1−6.
[9] Liu H, Wang S, Wang J, et al. Energy metabolism in health and diseases. Sig Transduct Target Ther, 2025; 10, 69.
[10] Wang Z, Zhang L, Qin C. Alzheimer’s disease pathogenesis: standing at the crossroad of lipid metabolism and immune response. Mol Neurodegeneration, 2025; 20, 67.
[11] Yang PY, Xin LM, Jie LW, et al. DJ1 Ameliorates AD-like Pathology in the Hippocampus of APP/PS1 Mice. Biomed Environ Sci, 2023; 36, 1028−44.
[12] Minhas PS, Jones JR, Latif-Hernandez A, et al. Restoring hippocampal glucose metabolism rescues cognition across Alzheimer’s disease pathologies. Science, 2024; 385, eabm6131.
[13] Song Q, Li W, Liu Y, et al. LDH-related Metabolic Alterations in Alzheimer’s Disease: Evidence from Clinical and Transcriptomic Analyses. Biomed Environ Sci, 2026; 39, 1−20.
[14] Prakash P, Manchanda P, Paouri E, et al. Amyloid-β induces lipid droplet-mediated microglial dysfunction via the enzyme DGAT2 in Alzheimer’s disease. Immunity. 2025; 58, 1536-1552.e8.